Patterson Belknap Webb & Tyler LLP announced the launch of BiologicsBlog.com, a source of insights, information and analysis related to biologics, including the legal developments, trends and changing regulation that impact the biotechnology industry.
BiologicsBlog.com will be among the few industry resources to explore the regulatory and legal framework for biosimilar and interchangeable biologic products created under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”). The BPCIA regulatory and litigation pathway is just beginning to take shape and the first biosimilars in U.S. history are likely to be approved this year.
The blog will be managed by Patterson Belknap’s Biotechnology and Intellectual Property Litigation practice groups, whose members are deeply involved in the complex issues facing the biotechnology industry. The team represents biotechnology, pharmaceutical and healthcare companies in a broad range of litigation matters, including patent infringement cases, AIA trials, patent licensing and other contractual disputes. It includes highly experienced trial attorneys with extensive technical knowledge, many of whom have advanced scientific degrees and industry experience in molecular and cell biology, biochemistry and chemistry.
Irena Royzman, Co-Chair of the Biotechnology Practice, noted, “As we developed the blog, our focus was on providing a valuable resource for our clients and the biotechnology industry at-large. We believe our in-depth coverage and analysis of the law concerning biologics and developments impacting the biotechnology industry will do that.”
